Affordable Access

Prolonged versus standard native E-coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma : final results of the EORTC-CLG randomized phase III trial 58951

Authors
  • Mondelaers, Veerle
  • Suciu, Stefan
  • De Moerloose, Barbara
  • Ferster, Alina
  • Mazingue, Francoise
  • Plat, Geneviève
  • Yakouben, Karima
  • Uyttebroeck, Anne
  • Lutz, Patrick
  • Costa, Vitor
  • Sirvent, Nicolas
  • Plouvier, Emmanuel
  • Munzer, Martine
  • Poirée, Maryline
  • Minckes, Odile
  • Millot, Frédéric
  • Plantaz, Dominique
  • Maes, Philip
  • Hoyoux, Claire
  • Cavé, Hélène
  • And 3 more
Publication Date
Jan 01, 2017
Source
Ghent University Institutional Archive
Keywords
Language
English
License
Unknown
External links

Abstract

Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma. The value of asparaginase was further addressed in a group of non-very high-risk patients by comparing prolonged (long-asparaginase) versus standard (short-asparaginase) native E. coli asparaginase treatment in a randomized part of the phase III 58951 trial of the European Organization for Research and Treatment of Cancer Children's Leukemia Group. The main endpoint was disease-free survival. Overall, 1,552 patients were randomly assigned to long-asparaginase (775 patients) or short-asparaginase (777 patients). Patients with grade >= 2 allergy to native E. coli asparaginase were switched to equivalent doses of Erwinia or pegylated E. coli asparaginase. The 8-year disease-free survival rate (+/- standard error) was 87.0 +/- 1.3% in the long-asparaginase group and 84.4 +/- 1.4% in the short-asparaginase group (hazard ratio: 0.87; P=0.33) and the 8-year overall survival rate was 92.6 +/- 1.0% and 91.3 +/- 1.2% respectively (hazard ratio: 0.89; P=0.53). An exploratory analysis suggested that the impact of long-asparaginase was beneficial in the National Cancer Institute standard-risk group with regards to disease-free survival (hazard ratio: 0.70; P=0.057), but far less so with regards to overall survival (hazard ratio: 0.89). The incidences of grade 3-4 infection during consolidation (25.2% versus 14.4%) and late intensification (22.6% versus 15.9%) and the incidence of grade 2-4 allergy were higher in the long-asparaginase arm (30% versus 21%). Prolonged native E. coli asparaginase therapy in consolidation and late intensification for our non-very high-risk patients did not improve overall outcome but led to an increase in infections and allergy.

Report this publication

Statistics

Seen <100 times